Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: Meta-analysis of quality-adjusted survival

Richard D. Gelber, Bernard F. Cole, Aron Goldhirsch, Carsten Rose, Bernard Fisher, C. Kent Osborne, Francesco Boccardo, Richard Gray, Nahida H. Gordon, Nils Olof Bengtsson, Paul Sevelda

Research output: Contribution to journalArticle

Abstract

Background. Adjuvant tamoxifen for early breast cancer provides an improvement in relapse-free (RFS) and overall survival (OS), especially for older women. We carried out a meta-analysis to find out whether the benefit of adding chemotherapy to tamoxifen outweighs its costs in terms of toxic effects for postmenopausal patients. Methods. The meta-analysis of quality-adjusted survival was based on data from 3920 patients aged 50 years or older with node-positive breast cancer randomly assigned in nine trials that compared combination chemotherapy plus tamoxifen with tamoxifen alone. The nine trials were included in the worldwide overview conducted by the early breast cancer trialists' collaborative group (EBCTCG). The quality-adjusted time without symptoms or toxicity (Q-TWIST) method was used to provide treatment comparisons incorporating differences in quality of life associated with subjective toxic effects of treatment and symptoms of disease relapse. Findings. Within 7 years of follow-up the modest benefit of increased RFS and OS for patients who received chemotherapy just balanced the costs in terms of acute toxic side-effects. Chemotherapy-treated patients gained an average of 5.4 months of RFS and 2 months of OS (neither statistically significant), cytotoxic treatment for between achieve these gains. No values of preference weights for time spent undergoing chemotherapy and time after relapse gave significantly more Q-TWIST with chemotherapy plus tamoxifen than with tamoxifen alone. Interpretation. Within 7 years of follow-up, adjuvant chemoendocrine therapy did not provide more quality-adjusted survival time than tamoxifen alone for women aged 50 years or older with node positive breast cancer. Better selection and administration of chemotherapy regimen, different scheduling of chemotherapy and tamoxifen, and appropriate use of patient and tumour characteristics may increase the therapeutic advantage of the combination.

Original languageEnglish
Pages (from-to)1066-1071
Number of pages6
JournalLancet
Volume347
Issue number9008
DOIs
Publication statusPublished - Apr 20 1996

Fingerprint

Tamoxifen
Adjuvant Chemotherapy
Meta-Analysis
Breast Neoplasms
Survival
Drug Therapy
Poisons
Recurrence
Therapeutics
Costs and Cost Analysis
Combination Drug Therapy
Quality of Life
Weights and Measures

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer : Meta-analysis of quality-adjusted survival. / Gelber, Richard D.; Cole, Bernard F.; Goldhirsch, Aron; Rose, Carsten; Fisher, Bernard; Osborne, C. Kent; Boccardo, Francesco; Gray, Richard; Gordon, Nahida H.; Bengtsson, Nils Olof; Sevelda, Paul.

In: Lancet, Vol. 347, No. 9008, 20.04.1996, p. 1066-1071.

Research output: Contribution to journalArticle

Gelber, RD, Cole, BF, Goldhirsch, A, Rose, C, Fisher, B, Osborne, CK, Boccardo, F, Gray, R, Gordon, NH, Bengtsson, NO & Sevelda, P 1996, 'Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: Meta-analysis of quality-adjusted survival', Lancet, vol. 347, no. 9008, pp. 1066-1071. https://doi.org/10.1016/S0140-6736(96)90277-9
Gelber, Richard D. ; Cole, Bernard F. ; Goldhirsch, Aron ; Rose, Carsten ; Fisher, Bernard ; Osborne, C. Kent ; Boccardo, Francesco ; Gray, Richard ; Gordon, Nahida H. ; Bengtsson, Nils Olof ; Sevelda, Paul. / Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer : Meta-analysis of quality-adjusted survival. In: Lancet. 1996 ; Vol. 347, No. 9008. pp. 1066-1071.
@article{40362d90c99b49ceab1b882cf96fc66a,
title = "Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: Meta-analysis of quality-adjusted survival",
abstract = "Background. Adjuvant tamoxifen for early breast cancer provides an improvement in relapse-free (RFS) and overall survival (OS), especially for older women. We carried out a meta-analysis to find out whether the benefit of adding chemotherapy to tamoxifen outweighs its costs in terms of toxic effects for postmenopausal patients. Methods. The meta-analysis of quality-adjusted survival was based on data from 3920 patients aged 50 years or older with node-positive breast cancer randomly assigned in nine trials that compared combination chemotherapy plus tamoxifen with tamoxifen alone. The nine trials were included in the worldwide overview conducted by the early breast cancer trialists' collaborative group (EBCTCG). The quality-adjusted time without symptoms or toxicity (Q-TWIST) method was used to provide treatment comparisons incorporating differences in quality of life associated with subjective toxic effects of treatment and symptoms of disease relapse. Findings. Within 7 years of follow-up the modest benefit of increased RFS and OS for patients who received chemotherapy just balanced the costs in terms of acute toxic side-effects. Chemotherapy-treated patients gained an average of 5.4 months of RFS and 2 months of OS (neither statistically significant), cytotoxic treatment for between achieve these gains. No values of preference weights for time spent undergoing chemotherapy and time after relapse gave significantly more Q-TWIST with chemotherapy plus tamoxifen than with tamoxifen alone. Interpretation. Within 7 years of follow-up, adjuvant chemoendocrine therapy did not provide more quality-adjusted survival time than tamoxifen alone for women aged 50 years or older with node positive breast cancer. Better selection and administration of chemotherapy regimen, different scheduling of chemotherapy and tamoxifen, and appropriate use of patient and tumour characteristics may increase the therapeutic advantage of the combination.",
author = "Gelber, {Richard D.} and Cole, {Bernard F.} and Aron Goldhirsch and Carsten Rose and Bernard Fisher and Osborne, {C. Kent} and Francesco Boccardo and Richard Gray and Gordon, {Nahida H.} and Bengtsson, {Nils Olof} and Paul Sevelda",
year = "1996",
month = "4",
day = "20",
doi = "10.1016/S0140-6736(96)90277-9",
language = "English",
volume = "347",
pages = "1066--1071",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Lancet Publishing Group",
number = "9008",

}

TY - JOUR

T1 - Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer

T2 - Meta-analysis of quality-adjusted survival

AU - Gelber, Richard D.

AU - Cole, Bernard F.

AU - Goldhirsch, Aron

AU - Rose, Carsten

AU - Fisher, Bernard

AU - Osborne, C. Kent

AU - Boccardo, Francesco

AU - Gray, Richard

AU - Gordon, Nahida H.

AU - Bengtsson, Nils Olof

AU - Sevelda, Paul

PY - 1996/4/20

Y1 - 1996/4/20

N2 - Background. Adjuvant tamoxifen for early breast cancer provides an improvement in relapse-free (RFS) and overall survival (OS), especially for older women. We carried out a meta-analysis to find out whether the benefit of adding chemotherapy to tamoxifen outweighs its costs in terms of toxic effects for postmenopausal patients. Methods. The meta-analysis of quality-adjusted survival was based on data from 3920 patients aged 50 years or older with node-positive breast cancer randomly assigned in nine trials that compared combination chemotherapy plus tamoxifen with tamoxifen alone. The nine trials were included in the worldwide overview conducted by the early breast cancer trialists' collaborative group (EBCTCG). The quality-adjusted time without symptoms or toxicity (Q-TWIST) method was used to provide treatment comparisons incorporating differences in quality of life associated with subjective toxic effects of treatment and symptoms of disease relapse. Findings. Within 7 years of follow-up the modest benefit of increased RFS and OS for patients who received chemotherapy just balanced the costs in terms of acute toxic side-effects. Chemotherapy-treated patients gained an average of 5.4 months of RFS and 2 months of OS (neither statistically significant), cytotoxic treatment for between achieve these gains. No values of preference weights for time spent undergoing chemotherapy and time after relapse gave significantly more Q-TWIST with chemotherapy plus tamoxifen than with tamoxifen alone. Interpretation. Within 7 years of follow-up, adjuvant chemoendocrine therapy did not provide more quality-adjusted survival time than tamoxifen alone for women aged 50 years or older with node positive breast cancer. Better selection and administration of chemotherapy regimen, different scheduling of chemotherapy and tamoxifen, and appropriate use of patient and tumour characteristics may increase the therapeutic advantage of the combination.

AB - Background. Adjuvant tamoxifen for early breast cancer provides an improvement in relapse-free (RFS) and overall survival (OS), especially for older women. We carried out a meta-analysis to find out whether the benefit of adding chemotherapy to tamoxifen outweighs its costs in terms of toxic effects for postmenopausal patients. Methods. The meta-analysis of quality-adjusted survival was based on data from 3920 patients aged 50 years or older with node-positive breast cancer randomly assigned in nine trials that compared combination chemotherapy plus tamoxifen with tamoxifen alone. The nine trials were included in the worldwide overview conducted by the early breast cancer trialists' collaborative group (EBCTCG). The quality-adjusted time without symptoms or toxicity (Q-TWIST) method was used to provide treatment comparisons incorporating differences in quality of life associated with subjective toxic effects of treatment and symptoms of disease relapse. Findings. Within 7 years of follow-up the modest benefit of increased RFS and OS for patients who received chemotherapy just balanced the costs in terms of acute toxic side-effects. Chemotherapy-treated patients gained an average of 5.4 months of RFS and 2 months of OS (neither statistically significant), cytotoxic treatment for between achieve these gains. No values of preference weights for time spent undergoing chemotherapy and time after relapse gave significantly more Q-TWIST with chemotherapy plus tamoxifen than with tamoxifen alone. Interpretation. Within 7 years of follow-up, adjuvant chemoendocrine therapy did not provide more quality-adjusted survival time than tamoxifen alone for women aged 50 years or older with node positive breast cancer. Better selection and administration of chemotherapy regimen, different scheduling of chemotherapy and tamoxifen, and appropriate use of patient and tumour characteristics may increase the therapeutic advantage of the combination.

UR - http://www.scopus.com/inward/record.url?scp=15844425226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15844425226&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(96)90277-9

DO - 10.1016/S0140-6736(96)90277-9

M3 - Article

C2 - 8602056

AN - SCOPUS:15844425226

VL - 347

SP - 1066

EP - 1071

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9008

ER -